The novel antimicrotubule agent cryptophycin 52 (LY355703) induces apoptosis via multiple pathways in human prostate cancer cells

Clinical Cancer Research

Volumn 8, Issue 12, 2002, Pages 3922-3932

  Drew, Lisa ^a   Fine, Robert L ^a   Do, Tamara N ^a   Douglas, Geoffrey P ^a   Petrylak, Daniel P ^a,b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b New York Presbyterian Hospital Columbia University Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; CASPASE 3; CASPASE 7; CRYPTOPHYCIN 52; LY355703; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; RAF PROTEIN; STAUROSPORINE; STRESS ACTIVATED PROTEIN KINASE;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RESISTANCE; CELL CYCLE; CELL DEATH; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PHOSPHORYLATION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; UPREGULATION;

ANDROGENS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-X PROTEIN; BLOTTING, WESTERN; CASPASES; CELL DIVISION; CYTOCHROME C GROUP; DEPSIPEPTIDES; ENZYME ACTIVATION; ENZYME INHIBITORS; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LACTAMS; LACTONES; MALE; MICROTUBULES; MITOGEN-ACTIVATED PROTEIN KINASES; POLY(ADP-RIBOSE) POLYMERASES; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; STAUROSPORINE; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0036897528     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Wilding, G. Endocrine control of prostate cancer. Cancer Surv., 23: 43-62, 1995.
2. Earhart, R. H. Docetaxel (Taxotere): Preclinical and general clinical information. Semin. Oncol., 26: 8-13, 1999.
3. Rowinsky, E. K. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu. Rev. Med., 48: 353-374, 1997.
4. Hudes, G. R., Nathan, F. E., Khater, C., Greenberg, R., Gomella, L., Stern, C., and McAleer, C. Paclitaxel plus estramustine in metastatic hormone refractory prostate cancer. Semin. Oncol., 22: 6-11, 1995.
5. Wang, L. G., Liu, X. M., Kreis, W., and Budman, D. R. The effect of antimicrotubule agents on signal transduction pathways of apoptosis: A review. Cancer Chemother. Pharmacol., 44: 355-361, 1999.
6. Blagosklonny, M. V., Schulte, T. W., Nguyen, P., Mimnaugh, E. G., Trepel, J., and Neckers, L. Taxol induction of p21WAF1 and p53 requires c-raf-1. Cancer Res., 55: 4623-4626, 1995.
7. Jones, N. A., Turner, J., McIlwrath, A. J., Brown, R., and Dive, C. Cisplatin- and paclitaxel-induced apoptosis in ovarian carcinoma cells and the relationship between bax and bak up-regulation and the functional status of p53. Mol. Pharmacol., 53: 819-826, 1998.
8. Blagosklonny, M. V., Giannakakou, P., El-Deiry, W. S., Kingston, D. G. I., Higgs, P. I., Neckers, L., and Fojo, T. Raf-1/bcl-2 phosphorylation: A step from microtubule damage to cell death. Cancer Res., 57: 130-135, 1997.
9. L is phosphorylated in malignant cells following microtubule disruption. Cancer Res., 58: 3331-3338, 1998.
10. Pucci, B., Bellincampi, L., Tafani, M., Masciullo, V., Melino, G., and Giordano, A. Paclitaxel induces apoptosis in Saos-2 cells with CD95L upregulation and bcl-2 phosphorylation. Exp. Cell Res., 252: 134-143, 1999.
11. Haldar, S., Chinatapalli, J., and Croce, C. M. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res., 56: 1253-1255, 1996.
12. L and bak expression. Clin. Cancer Res., 3: 2039-2046, 1997.
13. Stein, C. A. Mechanisms of action of taxanes in prostate cancer. Semin. Oncol., 26: 3-7, 1999.
14. Wang, T-H., Wang, H-S., Ichijo, H., Giannakakou, P., Foster, J. S., Fojo, T., and Wimalasena, J. Microtubule-inteffering agents activate c-Jun N-terminal kinase/stress-activated protein kinase through both ras and apoptosis signal-regulating pathways. J. Biol Chem., 273: 4928-4936, 1998.
15. Wang, T-H., Popp, D. M., Wang, H. S., Saitoh, M., Mural, J. G., Henley, D. C., Ichijo, H., and Wimalasena, J. Microtubule dysfunction induced by paclitaxel initiates apoptosis through both c-Jun N-terminal (JNK)-dependent and -independent pathways in ovarian cancer cells. J. Biol. Chem., 274: 8208-8216, 1999.
16. Stone, A. A., and Chambers, T. C. Microtubule inhibitors elicit differential effects on MAP kinase (JNK, ERK and p38) signaling pathways in human KB-3 carcinoma cells. Exp. Cell Res., 254: 110-119, 2000.
17. Suzuki, A., Kawabata, T., and Kato, M. Necessity of interleukin-1β-converting enzyme cascade in taxotere-initiated death signaling. Eur. J. Pharmacol., 343: 87-92, 1998.
18. Panvichian, R., Orth, K., Pilat, M. J., Day, M. L., Day, K. C., Yee, C., Kamradt, J. M., and Pienta, K. J. Signaling network of paclitaxel-induced apoptosis in the LNCaP prostate cancer cell line. Urology, 54: 746-752, 1999.
19. Trimurtulu, G., Ohtani, I., Patterson, G. M. L., Moore, R. E., Corbett, T. H., Valeriote, F. A., and Demchik, L. Total structures of cryptophycins, potent antitumor depsipeptides from the blue-green alga Nostoc sp. strain GSV. J. Am. Chem. Soc., 116: 4729-4737, 1994.
20. Panda, D., Williams, D. C., Wagner, M. M., Paul, D. C., Habeck, L. L., Mendelsohn, L. G., Shih, C., Moore, R. E., and Wilson, L. Inhibition of microtubule polymerization and dynamics by two novel cryptophycins, cryptophycins 52 and 55. Proc. Am. Assoc. Cancer Res., 38: 225, 1997.
21. Panda, D., DeLuca, K., Williams, D., Jordan, M. A., and Wilson, L. Antiproliferative mechanism of action of cryptophycin 52: Kinetic stabilization of microtubule dynamics by high affinity binding to microtubule ends. Proc. Natl. Acad. Sci. USA, 95: 9313-9318, 1998.
22. Corbett, T., Valeriote, F., Simpson, C., Moore, R., Tius, M., Barrow, R., Hemscheidt, T., Liang, J., Paik, S., Polin, L., Pugh, S., Kushner, J., Harrison, S., Shih, C., and Martinelli, M. Preclinical antitumor activity of cryptophycin-52/55 (C-52;C-55) against mouse tumors. Proc. Am. Assoc. Cancer Res., 38: 225, 1997.
23. Polin, L., Valeriote, F., Moore, R., Tius, M. Barrow, R., Hemscheidt, T., Liang, J., Paik, S., White, K., Harrison, S., Shih, C., Martinelli, M., and Corbett, T. Preclinical antitumor activity of cryptophycin-52/55 (C-52;C-55) against human tumors in SCID mice. Proc. Am. Assoc. Cancer Res., 38: 225, 1997.
24. Schultz, R. M., Shih, C., Harrison, S., Martinelli, M. J., Toth, J. E., and Andis, S. L. In vitro antiproliferative activity of the epoxide cryptophycin analogue, LY355703. Proc. Am. Assoc. Cancer Res., 38: 225-226, 1997.
25. Williams, D. C., Wagner, M. M., Law, K. L., Shepard, R. L., Paul, D. C., Starling, J. J., Dantzig, A. H., Moore, R. W., and Shih, C. In vitro pharmacology of cryptophycin 52 (LY355703) and cryptophycin 55 (LY355702) in human tumor cell lines. Proc. Am. Assoc. Cancer Res., 38: 226, 1997.
26. Worzalla, J. F., Cao, J., Ehlhardt, W. J., Harrison, S. D., Law, K. L., Martinelli, M. J., Self, T. D., Starling, J. J., Shih, C., Theobald, K. S., Toth, J. E., Zimmermann, J. L., and Corbett, J. H. LY355702 and LY355703, new cryptophycin analogues with antitumor activity against human tumor xenografts. Proc. Am. Assoc. Cancer Res., 38: 225, 1997.
27. Wagner, M. M., Paul, D. C., Shih, C., Jordan, M. A., Wilson, L., and Williams, D. C. In vitro pharmacology of cryptophycin 52 (LY355703) in human tumor cell lines. Cancer Chemother. Pharmacol., 43: 115-125, 1999.
28. Webber, M. M., Bello, D., and Quader, S. Immortalized and tumorigenic adult human prostatic epithelial cell lines: Characteristics and applications. Part 3. Oncogenes, suppressor genes and applications. Prostate, 30: 130-142, 1997.
29. Raffo, A. J., Perlman, H., Chen, M-W., Day, M. L., Streitman, J. S., and Buttyan, R. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res., 55: 4438-4445, 1995.
30. Cohen, G. M. Caspases: The executioners of apoptosis. Biochem. J., 326: 1-16, 1997.
31. Panvichian, R., Orth, K., Day, M. L., Day, K. C., Pilat, M. J., and Pienta, K. J. Paclitaxel-associated multinucleation is permitted by the inhibition of caspase activation: A potential early step in drug resistance. Cancer Res., 58: 4667-4672, 1998.
32. Denmeade, S. R., Lin, X. S., Tombal, B., and Isaacs, J. T. Inhibition of caspase activity does not prevent the signaling phase of apoptosis in prostate cancer cells. Prostate, 39: 269-279, 1999.
33. Marcelli, M., Cunningham, G. R., Walkup, M., He, Z., Sturgis, L., Kagan, C., Mannucci, R., Nicoletti, I., Teng, B., and Denner, L. Signaling pathway activated during apoptosis of the prostate cancer cell line LNCaP: Overexpression of caspase-7 as a new gene therapy strategy for prostate cancer. Cancer Res., 59: 382-390, 1999.
34. Marcelli, M., Cunningham, G. R., Haidacher, S. J., Padayatty, S. J., Sturgis, L., Kagan, C., and Denner, L. Caspase-7 is activated during lovastatin-induced apoptosis of the prostate cancer cell line LNCaP. Cancer Res., 58: 76-83, 1998.
35. L and bcl-2. EMBO J., 16: 968-977, 1997.
36. Haldar, S., Jena, N., and Croce, C. M. Inactivation of bcl-2 by phosphorylation. Proc. Natl. Acad. Sci. USA, 92: 4507-4511, 1995.
37. Uhlman, E. J., D'Sa-Eipper, C., Subramanian, A. J., Wagner, A. J., Hay, N., and Chinnadurai, G. Deletion of a nonconserved region of bcl-2 confers a novel gain of function: suppression of apoptosis with concomitant cell proliferation. Cancer Res., 56: 2506-2509, 1996.
38. Gangemi, R. M., Santamaria, B., Bargellesi, A., Cosulich, E., and Fabbi, M. Late apoptotic effects of taxanes on K562 erythroleukemia cells: Apoptosis is delayed upstream of caspase-3 activation. Int. J. Cancer, 85: 527-533, 2000.
39. Ling, Y. H., Tornos, C., and Perez-Soler, R. Phosphorylation of bcl-2 is a marker of M phase events and not a determinant of apoptosis. J. Biol. Chem., 273: 18984-18991, 1998.
40. s and bax induce different apoptotic pathways in PC-12 cells. Oncogene, 19: 1783-1793, 2000.
41. L inhibits Ara-C-induced CPP32/Yama protease activity and apoptosis of human acute myelogenous leukemia HL-60 cells. Cancer Res., 56: 4743-4748, 1996.
42. Mathiasen, I. S., Ladermann, U., and Jaattela, M. Apoptosis induced by vitamin D compounds in breast cancer cells is inhibited by bcl-2 but does not involve known caspases or p53. Cancer Res., 59: 4848-4856, 1999.
43. 2-terminal protein kinase pathway in the cellular response to adriamycin and other chemotherapeutic drugs. J. Biol. Chem., 271: 30950-30955, 1996.
44. Shtil, A. A., Mandlekar, S., Yu, R., Walter, R. J., Hagen, K., Tan, T. H., and Roninson, I. B. Differential regulation of mitogen-activated protein kinases by microtubule-binding agents in human breast cancer cells. Oncogene, 18: 377-384, 1999.
45. Chen, Y-R., Zhou, G., and Tan, T-H. c-Jun N-terminal kinase mediates apoptotic signaling induced by N-(4-hydroxyphenyl)retinamide. Mol. Pharmacol., 56: 1271-1279, 1999.
46. Xia, Z., Dickens, M., Raingeaud, J., Davis, R. J., and Greenberg, M. E. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science (Wash. DC), 270: 1326-1331, 1995.